GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Shandong Jincheng Pharmaceutical Group Co Ltd (SZSE:300233) » Definitions » Return-on-Tangible-Asset

Shandong Jincheng Pharmaceutical Group Co (SZSE:300233) Return-on-Tangible-Asset : 3.80% (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shandong Jincheng Pharmaceutical Group Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Shandong Jincheng Pharmaceutical Group Co's annualized Net Income for the quarter that ended in Jun. 2024 was ¥190 Mil. Shandong Jincheng Pharmaceutical Group Co's average total tangible assets for the quarter that ended in Jun. 2024 was ¥5,008 Mil. Therefore, Shandong Jincheng Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 was 3.80%.

The historical rank and industry rank for Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300233' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -11.54   Med: 6.29   Max: 10.92
Current: 4.04

During the past 13 years, Shandong Jincheng Pharmaceutical Group Co's highest Return-on-Tangible-Asset was 10.92%. The lowest was -11.54%. And the median was 6.29%.

SZSE:300233's Return-on-Tangible-Asset is ranked better than
56.28% of 1576 companies
in the Chemicals industry
Industry Median: 3.225 vs SZSE:300233: 4.04

Shandong Jincheng Pharmaceutical Group Co Return-on-Tangible-Asset Historical Data

The historical data trend for Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Jincheng Pharmaceutical Group Co Return-on-Tangible-Asset Chart

Shandong Jincheng Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.22 -11.54 2.45 5.74 3.46

Shandong Jincheng Pharmaceutical Group Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.11 2.43 3.31 6.55 3.80

Competitive Comparison of Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset

For the Chemicals subindustry, Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset falls into.



Shandong Jincheng Pharmaceutical Group Co Return-on-Tangible-Asset Calculation

Shandong Jincheng Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=174.709/( (5020.709+5073.653)/ 2 )
=174.709/5047.181
=3.46 %

Shandong Jincheng Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=190.48/( (5054.899+4961.004)/ 2 )
=190.48/5007.9515
=3.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2024) net income data.


Shandong Jincheng Pharmaceutical Group Co  (SZSE:300233) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Shandong Jincheng Pharmaceutical Group Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Shandong Jincheng Pharmaceutical Group Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Jincheng Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Shuangshan Road, Zichuan Economic Development Zone, Shandong, Zibo, CHN, 255100
Shandong Jincheng Pharmaceutical Group Co Ltd is engaged in the research and development, production and sale of III and IV cephalosporin intermediates and biopharmaceuticals. It offers characteristic bulk drugs, pharmaceutical intermediates, and fine chemicals. The company distributes its products within domestic market and to overseas markets.
Executives
Yang Xiu Liang Executives
Zhang Xue Bo Director
Zheng Geng Xiu Director
Zhao Ye Qing Director
Sun Rui Mei Executives
Cui Xi Li Executives
Zhao Hong Fu Director
Fu Miao Qing Executives
Zhu Xiao Gang Directors, executives
Li Jia Quan Directors, executives
Guo Fang Shui Supervisors
Chou Qiang Securities Affairs Representative

Shandong Jincheng Pharmaceutical Group Co Headlines

No Headlines